TY - JOUR
T1 - The ENIGMA Consortium
T2 - large-scale collaborative analyses of neuroimaging and genetic data
AU - Thompson, P.M.
AU - Stein, J.L.
AU - Medland, S.E.
AU - Hibar, D.P.
AU - Vasquez, A.A.
AU - Renteria, M.E.
AU - Toro, R.
AU - Jahanshad, N.
AU - Schumann, G.
AU - Franke, B.
AU - Brouwer, R.M.
AU - Hulshoff Pol, H.E.
AU - Kahn, R.S.
AU - Mandl, R.C.W.
AU - Ophoff, R.A.
AU - Schnack, H.G.
AU - van den Heuvel, M.P.
AU - van Haren, N.E.M.
AU - et al, X
AU - Drevets, W.C.
PY - 2014/6
Y1 - 2014/6
N2 - The Enhancing NeuroImaging Genetics through Meta-Analysis (ENIGMA) Consortium is a collaborative network of researchers working together on a range of large-scale studies that integrate data from 70 institutions worldwide. Organized into Working Groups that tackle questions in neuroscience, genetics, and medicine, ENIGMA studies have analyzed neuroimaging data from over 12,826 subjects. In addition, data from 12,171 individuals were provided by the CHARGE consortium for replication of findings, in a total of 24,997 subjects. By meta-analyzing results from many sites, ENIGMA has detected factors that affect the brain that no individual site could detect on its own, and that require larger numbers of subjects than any individual neuroimaging study has currently collected. ENIGMA's first project was a genome-wide association study identifying common variants in the genome associated with hippocampal volume or intracranial volume. Continuing work is exploring genetic associations with subcortical volumes (ENIGMA2) and white matter microstructure (ENIGMA-DTI). Working groups also focus on understanding how schizophrenia, bipolar illness, major depression and attention deficit/hyperactivity disorder (ADHD) affect the brain. We review the current progress of the ENIGMA Consortium, along with challenges and unexpected discoveries made on the way.
AB - The Enhancing NeuroImaging Genetics through Meta-Analysis (ENIGMA) Consortium is a collaborative network of researchers working together on a range of large-scale studies that integrate data from 70 institutions worldwide. Organized into Working Groups that tackle questions in neuroscience, genetics, and medicine, ENIGMA studies have analyzed neuroimaging data from over 12,826 subjects. In addition, data from 12,171 individuals were provided by the CHARGE consortium for replication of findings, in a total of 24,997 subjects. By meta-analyzing results from many sites, ENIGMA has detected factors that affect the brain that no individual site could detect on its own, and that require larger numbers of subjects than any individual neuroimaging study has currently collected. ENIGMA's first project was a genome-wide association study identifying common variants in the genome associated with hippocampal volume or intracranial volume. Continuing work is exploring genetic associations with subcortical volumes (ENIGMA2) and white matter microstructure (ENIGMA-DTI). Working groups also focus on understanding how schizophrenia, bipolar illness, major depression and attention deficit/hyperactivity disorder (ADHD) affect the brain. We review the current progress of the ENIGMA Consortium, along with challenges and unexpected discoveries made on the way.
KW - Genetics
KW - MRI
KW - GWAS
KW - Consortium
KW - Meta-analysis
KW - Multi-site
KW - GENOME-WIDE ASSOCIATION
KW - CORTICAL SURFACE-AREA
KW - WHITE-MATTER MICROSTRUCTURE
KW - MULTIVARIATE PARALLEL ICA
KW - TENSOR-BASED MORPHOMETRY
KW - QUANTITATIVE TRAIT LOCI
KW - VOXEL-BASED MORPHOMETRY
KW - HUMAN BRAIN STRUCTURE
KW - DISEASE RISK VARIANT
KW - BODY-MASS INDEX
U2 - 10.1007/s11682-013-9269-5
DO - 10.1007/s11682-013-9269-5
M3 - Article
C2 - 24399358
SN - 1931-7557
VL - 8
SP - 153
EP - 182
JO - Brain Imaging and Behavior
JF - Brain Imaging and Behavior
IS - 2
ER -